IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

CHROMADEX, INC. and TRUSTEES OF DARTMOUTH COLLEGE,

Plaintiffs,

C.A. No. 18-1434-CFC

v.

ELYSIUM HEALTH, INC.,

Defendant.

PROPOSED CLAIM CONSTRUCTION ORDER

As set forth by the Court at the claim construction hearing held on December 17, 2020, IT IS HEREBY ORDERED that the claim terms below are construed as follows:

TERM	PATENT(S) / CLAIM(S)	COURT'S CONSTRUCTION
"nicotinamide	'807 Patent: Claims 1 and 2	"nicotinamide riboside
riboside"	'086 Patent: Claim 2	or a derivative (e.g., L-valine or L-phenylalanine esters) of nicotinamide riboside"
"isolated nicotinamide riboside"	'807 Patent: Claim 1	"nicotinamide riboside that is separated or substantially free from at least some of the other components associated with the source of the nicotinamide riboside"
"the nicotinamide riboside is isolated from a natural or synthetic source"	'807 Patent: Claim 2 '086 Patent: Claim 2	"the nicotinamide riboside is isolated from a natural source or synthetic source and is not chemically synthesized"
"in combination with one or more of tryptophan, nicotinic acid, or nicotinamide"	'807 Patent: Claim 1	"both isolated nicotinamide riboside and one or more of tryptophan, nicotinic acid, or nicotinamide are found in the composition"
"increases NAD+ biosynthesis upon oral administration"	'807 Patent: Claim 1	"increases NAD+ biosynthesis upon oral administration to an animal relative to the level of NAD+ biosynthesis if the composition were not administered to an animal"

TERM	PATENT(S) / CLAIM(S)	COURT'S CONSTRUCTION
"pharmaceutical	'086 Patent: Claim 2	"a composition that can
composition"		be used to improve or prolong the health or well-being of humans or other animals"

SO ORDERED this 5th day of January, 2020.

The Honorable Colm F. Connolly United States District Judge